World ADC San Diego Conference Highlights Growing Industry Focus on Antibody-Drug Conjugates
The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.
Immutep's Eftilagimod Alpha Combination Meets Primary Endpoint in Phase II Soft Tissue Sarcoma Trial
Immutep's EFTISARC-NEO Phase II trial demonstrated that eftilagimod alpha combined with radiotherapy and pembrolizumab achieved a 50% median tumor hyalinization/fibrosis rate, significantly exceeding the 35% prespecified benchmark.
Merck Defends Current GARDASIL 9 Dosing Amid Regulatory Discussions on Single-Dose Regimen
Merck affirmed its position that CDC recommendations should remain consistent with approved GARDASIL 9 labeling until sufficient data enables FDA and European Commission to license alternate dosing regimens.
Merus Reports Promising Survival Data for Petosemtamab-Keytruda Combination in Metastatic Head and Neck Cancer
Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.
Eisai to Present Long-Term LEAP-002 Data and Novel Pipeline Advances at ASCO 2025
Eisai will showcase long-term follow-up data from the Phase 3 LEAP-002 study evaluating lenvatinib plus pembrolizumab versus lenvatinib monotherapy in first-line unresectable hepatocellular carcinoma treatment.
Merck and imec Partner to Develop Advanced Microphysiological Systems Platform for Drug Discovery
Merck and imec have announced a strategic partnership to develop an advanced Microphysiological Systems (MPS) platform that aims to improve drug discovery efficiency and reduce reliance on animal testing.
VERAXA Biotech Appoints Oncology Veteran Rick Austin as Chief Scientific Officer to Advance Novel Cancer Therapies
Dr. Rick Austin, with over 25 years of oncology drug development experience, joins VERAXA Biotech as Chief Scientific Officer to advance the company's BiTAC platform and clinical-stage pipeline.
CytomX Doses First Patient in Combination Trial of CX-801 with Keytruda for Metastatic Melanoma
CytomX Therapeutics has dosed the first patient in a Phase 1 trial combining its masked interferon alpha-2b (CX-801) with Merck's Keytruda in patients with metastatic melanoma.
Astellas to Present New Long-Term Survival Data for Cancer Therapies at ASCO 2025
Astellas will showcase 16 abstracts at the 2025 ASCO Annual Meeting, including two oral presentations highlighting long-term survival data for its oncology portfolio.
Merck and Daiichi Sankyo Launch Phase 3 Trial of Novel B7-H3 Targeted ADC for Advanced Esophageal Cancer
The IDeate-Esophageal01 Phase 3 trial has begun evaluating ifinatamab deruxtecan, a potential first-in-class B7-H3 directed antibody-drug conjugate, against standard chemotherapy in advanced esophageal squamous cell carcinoma.